Boston Scientific Corporation has entered into an agreement to acquire Valencia Technologies Corporation to expand its urology offerings, specifically targeting overactive bladder treatment with the eCoin® System.

Target Information

Boston Scientific Corporation has announced a definitive agreement to acquire Valencia Technologies Corporation, a leading private medical technology company dedicated to developing innovative solutions for bladder dysfunction. The standout product from Valencia Technologies is the eCoin® System, an implantable tibial nerve stimulation (ITNS) device designed to address urge urinary incontinence (UUI), a prevalent symptom of overactive bladder (OAB). This acquisition is essential for expanding Boston Scientific's urology offerings.

With almost 30 million adults aged 40 and above in the United States suffering from bothersome symptoms of OAB, the eCoin System presents a significant opportunity for treatment enhancement. The device was FDA-approved in 2022 and is implanted under the skin near the ankle through a minimally invasive procedure. Following its implantation, it intermittently stimulates the tibial nerve, improving brain-bladder communication. Clinical trials showed that 68% of patients experienced at least a 50% reduction in UUI episodes post-implementation.

Industry Overview

The healthcare landscape in the United States continues to experience significant shifts, particularly in the area of urology and bladder treatment. Overactive bladder remains a pressing public health issue